Eli Lilly | LLY - Nettoeinkommen

Aktienkurs
884.77
Täglich Wechseln
0.81 0.09%
Monatlich
-0.21%
Jährlich
0.85%
Q2 Prognose
865.04




Nettoeinkommen Veränderung Datum
AbbVie USD 1.82B 1.63B 2025-12
Abbott USD 1.08B 699M 2026-03
ALKERMES USD 49.34M 33.42M 2025-12
Amgen USD 1.33B 1.88B 2025-12
AstraZeneca USD 2.33B 207M 2025-12
Baxter International USD -1.13B 1.08B 2025-12
Biogen USD 466.5M 168.3M 2025-09
Bristol-Myers Squibb USD 1.09B 1.11B 2025-12
Coherus Biosciences USD -37.64M 2.11M 2025-12
Drreddys Laboratories INR 12.1B 2.08B 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Gilead Sciences USD 2.18B 869M 2025-12
GlaxoSmithKline GBP 636M 1.38B 2025-12
Glaxosmithkline GBP 846.06M 1.87B 2025-12
J&J USD 5.24B 119M 2026-03
Medtronic USD 1.14B 231M 2025-12
Merck USD 2.96B 2.82B 2025-12
Neurocrine Biosciences USD 209.5M 102M 2025-09
Novartis USD 2.41B 1.52B 2025-12
Novartis USD 2.41B 1.52B 2025-12
Novo Nordisk DKK 26.89B 388M 2025-12
Perrigo USD -1.42B 1.43B 2025-12
Pfizer USD -1.65B 5.19B 2025-12
Phibro Animal Health USD 27.46M 932K 2025-12
Prestige Brands USD 46.7M 22.44M 2025-12
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Roche Holding CHF 5.47B 1.76B 2025-12
Sanofi EUR 1.61B 2.42B 2026-03
Sanofi EUR -801M 3.6B 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12
Zoetis USD 603M 118M 2025-12